Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05770765
Recruiting Observational

Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases

NCT05770765 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Sacro Cuore Don Calabria di Negrar
Phase
Observational
Started
2019-10-30
Last updated
2023-03-15

Condition(s) studied

Infections

Study summary

This is the protocol that formalizes the establishment of the TROPICA-BIOBANK biobank

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: • Informed consent (for healthy volounteers also: age \> 18 years, health status ascertained by laboratory tests, electrocardiogram and medical examination) Exclusion Criteria: * History of alcohol/drug abuse * Pregnant or breastfeeding women, unless there are justified and documented needs

Primary outcome measure(s)

  • Presence of a viral, bacterial or parasitic pathogen — 40 years
    Result of laboratory tests on the pathogen responsible for the disease of interest

Trial sites (1)

FacilityCityRegionStatus
IRCCS Sacro Cuore Don Calabria hospital Negrar Verona Recruiting

More IRCCS Sacro Cuore Don Calabria di Negrar trials in Italy

Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers Recruiting
Pilot Randomized Study for Treatment Volume De-Escalation for Spinal Metastases With Stereotactic Body Radiation Therapy Recruiting
Insights Into Tick-Borne Diseases: a Study From an Endemic Area of Northern Italy Recruiting
Evaluation of the Rapid Diagnostic Test SsRT+ for Strongyloides Stercoralis Active, not recruiting
OBSERVATIONAL STUDY ON VIRAL SHEDDING AND IMMUNOLOGICAL RESPONSE OF OROPOUCHE VIRUS Recruiting

Other trials for the same condition

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) Recruiting
Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE) Recruiting
Susceptibility to Infectious Diseases in obEsity: an endocRine trAnslational socioLogic Evaluation, "SIDERALE" Recruiting
Evaluation and Assessment for Communicable Diseases in Migrants Hosted in Reception Centers Recruiting
Efficacy of a 2'-Fucosylactose-based Food Supplement on the Prevention of Respiratory and Gastrointestinal Infections. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05770765 on ClinicalTrials.gov ↗ ← All trials in Italy